Biotech Values

[DewDiligence]

Good catch, ghmm! This is a notable trial design insofar as BI is sticking with ribavirin in all trial arms. I presume BI has replicon data showing that the BI 207127 + BI 201335 combination is strongly boosted by ribavirin.

The clinicaltrials.gov entry says, “Study First Received: May 3, 2010,” which explains why BI’s program is not included in #msg-51233708.